Eli Lilly Return on Tangible Equity 2010-2024 | LLY
Current and historical return on tangible equity values for Eli Lilly (LLY) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Eli Lilly Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-09-30 |
$8.37B |
$2.02B |
967.91% |
| 2024-06-30 |
$7.34B |
$1.23B |
1559.02% |
| 2024-03-31 |
$6.14B |
$1.20B |
2994.63% |
| 2023-12-31 |
$5.24B |
$-0.98B |
-8698.76% |
| 2023-09-30 |
$4.99B |
$0.44B |
8384.87% |
| 2023-06-30 |
$6.50B |
$0.17B |
-2470.72% |
| 2023-03-31 |
$5.69B |
$0.14B |
-576.15% |
| 2022-12-31 |
$6.25B |
$-0.50B |
-416.68% |
| 2022-09-30 |
$6.03B |
$-0.85B |
-304.71% |
| 2022-06-30 |
$5.69B |
$-2.73B |
-209.09% |
| 2022-03-31 |
$6.13B |
$-1.91B |
-183.43% |
| 2021-12-31 |
$5.58B |
$-2.43B |
-136.80% |
| 2021-09-30 |
$5.97B |
$-3.82B |
-123.89% |
| 2021-06-30 |
$6.07B |
$-5.21B |
-111.47% |
| 2021-03-31 |
$6.09B |
$-4.87B |
-102.65% |
| 2020-12-31 |
$6.19B |
$-5.39B |
-91.01% |
| 2020-09-30 |
$5.57B |
$-6.32B |
-75.75% |
| 2020-06-30 |
$5.62B |
$-7.16B |
-74.65% |
| 2020-03-31 |
$5.53B |
$-8.35B |
-72.59% |
| 2019-12-31 |
$8.32B |
$-7.60B |
-110.63% |
| 2019-09-30 |
$7.95B |
$-7.00B |
-226.99% |
| 2019-06-30 |
$7.84B |
$-7.55B |
-3762.11% |
| 2019-03-31 |
$6.26B |
$-7.93B |
244.63% |
| 2018-12-31 |
$3.23B |
$8.47B |
52.94% |
| 2018-09-30 |
$0.45B |
$6.17B |
9.37% |
| 2018-06-30 |
$-0.14B |
$3.52B |
-2.97% |
| 2018-03-31 |
$1.12B |
$6.26B |
21.22% |
| 2017-12-31 |
$-0.20B |
$3.27B |
-4.05% |
| 2017-09-30 |
$2.23B |
$6.32B |
39.37% |
| 2017-06-30 |
$2.45B |
$5.34B |
42.09% |
| 2017-03-31 |
$2.19B |
$5.20B |
36.85% |
| 2016-12-31 |
$2.74B |
$5.75B |
44.45% |
| 2016-09-30 |
$2.44B |
$6.97B |
40.06% |
| 2016-06-30 |
$2.47B |
$5.82B |
41.09% |
| 2016-03-31 |
$2.32B |
$6.10B |
38.62% |
| 2015-12-31 |
$2.41B |
$5.52B |
40.19% |
| 2015-09-30 |
$2.36B |
$6.57B |
32.32% |
| 2015-06-30 |
$2.06B |
$5.84B |
23.18% |
| 2015-03-31 |
$2.19B |
$6.05B |
20.38% |
| 2014-12-31 |
$2.39B |
$10.75B |
18.71% |
| 2014-09-30 |
$2.69B |
$12.93B |
20.03% |
| 2014-06-30 |
$3.39B |
$13.33B |
25.49% |
| 2014-03-31 |
$3.86B |
$14.15B |
30.53% |
| 2013-12-31 |
$4.68B |
$13.31B |
40.02% |
| 2013-09-30 |
$4.78B |
$12.44B |
43.96% |
| 2013-06-30 |
$4.91B |
$10.73B |
46.62% |
| 2013-03-31 |
$4.63B |
$10.34B |
45.63% |
| 2012-12-31 |
$4.09B |
$10.02B |
41.13% |
| 2012-09-30 |
$4.12B |
$11.03B |
43.19% |
| 2012-06-30 |
$4.03B |
$9.17B |
43.60% |
| 2012-03-31 |
$4.30B |
$9.56B |
46.36% |
| 2011-12-31 |
$4.35B |
$8.41B |
47.29% |
| 2011-09-30 |
$4.66B |
$9.84B |
51.83% |
| 2011-06-30 |
$4.73B |
$9.32B |
55.25% |
| 2011-03-31 |
$4.88B |
$9.20B |
62.75% |
| 2010-12-31 |
$5.07B |
$7.59B |
71.61% |
| 2010-09-30 |
$4.82B |
$8.10B |
72.53% |
| 2010-06-30 |
$4.45B |
$6.20B |
72.36% |
| 2010-03-31 |
$4.26B |
$6.43B |
73.54% |
| 2009-12-31 |
$4.33B |
$5.83B |
83.94% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$719.145B |
$34.124B |
|
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
|
